- Open Access
Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer
- Hanseul Yang†1,
- Chan Kim†1,
- Min-Ju Kim2,
- Reto A Schwendener3,
- Kari Alitalo4,
- Warren Heston5,
- Injune Kim1,
- Wun-Jae Kim2Email author and
- Gou Young Koh1Email author
© Yang et al; licensee BioMed Central Ltd. 2011
Received: 20 October 2010
Accepted: 11 April 2011
Published: 11 April 2011
Most bladder cancer patients experience lymphatic metastasis in the course of disease progression, yet the relationship between lymphangiogenesis and lymphatic metastasis is not well known. The aim of this study is to elucidate underlying mechanisms of how expanded lymphatic vessels and tumor microenvironment interacts each other and to find effective therapeutic options to inhibit lymphatic metastasis.
The orthotopic urinary bladder cancer (OUBC) model was generated by intravesical injection of MBT-2 cell lines. We investigated the angiogenesis, lymphangiogenesis, and CD11b+/CD68+ tumor-associated macrophages (TAM) by using immunofluorescence staining. OUBC displayed a profound lymphangiogenesis and massive infiltration of TAM in primary tumor and lymphatic metastasis in lymph nodes. TAM flocked near lymphatic vessels and express higher levels of VEGF-C/D than CD11b- cells. Because VEGFR-3 was highly expressed in lymphatic vascular endothelial cells, TAM could assist lymphangiogenesis by paracrine manner in bladder tumor. VEGFR-3 expressing adenovirus was administered to block VEGF-C/D signaling pathway and clodronate liposome was used to deplete TAM. The blockade of VEGF-C/D with soluble VEGF receptor-3 markedly inhibited lymphangiogenesis and lymphatic metastasis in OUBC. In addition, the depletion of TAM with clodronate liposome exerted similar effects on OUBC.
VEGF-C/D are the main factors of lymphangiogenesis and lymphatic metastasis in bladder cancer. Moreover, TAM plays an important role in these processes by producing VEGF-C/D. The inhibition of lymphangiogenesis could provide another therapeutic target to inhibit lymphatic metastasis and recurrence in patients with invasive bladder cancer.
Bladder cancer ranks as the second most common genitourinary cancer and is associated with frequent distant metastasis at the time of both initial diagnosis and recurrence [1, 2]. Even though radical cystectomy and lymph node dissection may be curative, about 50% of patients with muscle-invasive bladder cancer eventually experience recurrence and metastases within 2 years of surgery, and most of them die of the disease . In patients with bladder cancer, the presence of metastasis in regional lymph node is a strong indicator of high recurrence (~55% at 5 years after cystectomy) and relatively poor survival rate (~45% at 5 years after cystectomy) [3, 4]. Intriguingly, patients and mice with bladder cancer display profound lymphatic vessels in the peripheral and central regions, which could be actively involved in lymphatic metastasis to lymph node [5, 6]. However, the underlying causes and driving forces of the expansion of lymphatic vessels in bladder cancer and underlying mechanisms of how the expanded lymphatic vessels are involved in bladder cancer metastasis to lymph nodes are poorly understood.
New lymphatic vessel formation, lymphangiogenesis, is potently induced by lymphangiogenic growth factors such as vascular endothelial growth factor (VEGF)-C and VEGF-D (VEGF-C/D) through binding and activation of their receptor tyrosine kinase, VEGF receptor-3 (VEGFR-3) [7, 8]. Proliferation, sprouting, expansion, enlargement and permeability of lymphatic vessels are largely affected by VEGF-C/D, and these processes facilitate cancer cell migration into the lymphatic vessels and spread to sentinel lymph node (SLN) [9–11]. Accordingly, blocking the VEGF-C/D-VEGFR-3 signaling pathway suppresses tumor lymphangiogenesis and lymph node metastasis in several tumor models [12–15]. These reports indicate that VEGF-C/D-mediated VEGFR-3 activation contributes to not only lymphatic vessel growth but also tumor cell dissemination via lymphatic vessels. In addition, VEGF-C/D is highly expressed in patients with bladder cancer [16, 17] and this expression is closely related to lymph node metastasis, but it has an inconsistent relationship with prognosis and survival rate. Yet, causative relationship between expression of VEGF-C/D, lymphangiogenesis and lymph node metastasis in the bladder cancer is not exactly known. It is known that CD11b+ tumor-associated macrophages (TAM) mainly express genes of the M2 type such as CD68, F4/80 and VEGFR-1, and is actively involved in tumor invasion and progression . Accumulating evidences indicate that TAM takes considerable part in promoting tumor angiogenesis and progression by abundant secretions of diverse angiogenic and lymphangiogenic growth factors [18–23]. However, involvement of TAM in lymphangiogenesis and lymphatic metastasis to SLN is unknown in the bladder cancer. Therefore, in this study, we investigated roles of VEGF-C/D and involvement of TAM in tumor lymphangiogenesis and lymphatic metastasis in the murine orthotopic urinary bladder cancer (OUBC) model. We found that OUBC induces profound lymphangiogenesis in the tumor and SLN and substantial lymphatic metastasis to SLN through VEGF-C/D-VEGFR-3 signaling pathway. Furthermore, CD11b+/CD68+ TAM was largely infiltrated around the tumor lymphatic vessels, and they were closely involved in the OUBC-induced lymphangiogenesis and lymphatic metastasis, possibly through secretary lymphangiogenic factors such as VEGF-C/D. Our findings provide a novel insight and useful treatment strategy how to control lymphatic metastasis in the patients with bladder cancer through suppression of VEGFR-3 signaling pathway.
Generation of OUBC mouse model
Eight-ten weeks old female C3H/HeN mice were purchased from the Orient Bio Inc. (Seongnam, Korea). Animal care and experimental procedures were performed under approval from the Animal Care Committees of KAIST. The murine bladder cancer cell line MBT-2 was originally obtained from Dr. Timothy Ratliff (University of Iowa, Iowa City, Iowa). The cell line initially originated from a transplantable N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumor in a C3H mouse . The MBT-2 cells were cultured in DMEM (Lonza, Walkersville, MD) containing 10% heat-inactivated fetal bovine serum (Cambrex, Walkersville, MD), 50 U/ml penicillin and 50 mg/ml streptomycin (Invitrogen, Grand Island, NY) in plastic tissue culture dishes at 37°C in a humidified atmosphere of 5% CO2. The cells were trypsinized and resuspended to a single cell suspension in PBS. The mice were anesthetized with an intramuscular injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). A 24G catheter (Becton Dickinson Korea Ltd., Korea) was inserted into the bladder through the urethra. The bladder epithelial layer was wounded with 100 μl of 0.1N HCl and NaOH to improve tumor cell implantation. 1 × 106 suspended MBT-2 cells in 100 μl of PBS were injected into the bladder cavity.
Histologic and morphometric analysis
Four weeks after MBT-2 cell implantation, bladder and SLN were sampled. For whole-mount staining, tissue samples were fixed in 1% paraformadehyde in PBS for 1 hr at room temperature (RT). Whole-mounted tissues were incubated for 3 hr at RT with hamster monoclonal anti-platelet endothelial cell adhesion molecule-1 (PECAM-1) antibody 1:1,000 (Chemicon International, Temecula, CA), or rabbit polyclonal anti-lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) antibody 1:1000 (Upstate, Lake Placid, NY) after a blocking the fixed tissues with 5% donkey serum in PBST (0.3% Triton X-100 in PBS) for 1 hr at RT. Samples were incubated for 2 hrs at RT with HRP-conjugated anti-hamster antibody 1:100 (Jackson ImmunoResearch, West Grove, PA) or HRP-conjugated anti-rabbit antibody, 1:100 (Amersham, Piscataway, NJ) and developed with 3,3'-diaminobenzidine (DAB) substrate kit according to manufacturer's instruction (Vector, Burlingame, CA). Samples were analyzed and photographed with a Zeiss Stemi SV6 stereomicroscope. For hematoxylin-eosin (H&E) and immunofluorescent staining of tissue sections, Samples were fixed in acetone for overnight at -20°C. Samples were embedded in paraffin block after serial incubation with methyl benzoate and xylene for 30 min at RT. Paraffin blocks were cut in 5-10 μm sections using Microm HM 335E rotary microtome (IMEB Inc, San Marcos, CA). Tissue sections were blocked with 5% goat or donkey serum in TBST (0.03% Triton X-100 in TBS) after dissolving the paraffin with xylene and acetone, immunostained with antibodies for 3 hr; these included hamster monoclonal anti-PECAM-1 antibody 1:200, rabbit polyclonal anti-LYVE-1 antibody 1:200, rat monoclonal anti-CD11b antibody 1:100 (BD Pharmingen, Franklin Lakes, NJ), rat monoclonal FITC-conjugated anti-CD11b antibody 1:50 (BD Pharminogen), mouse monoclonal anti-Cytokeratin antibody (Abcam Inc, Cambridge, MA), rat monoclonal FITC-conjugated anti-CD68 antibody 1:100 (Serotec Ltd., Oxford, UK), rat monoclonal anti-F4/80 antibody 1:100 (Research Diagnostics Inc., Flanders, NJ), goat polyclonal anti-VEGFR-3 antibody 1:100 (R&D Systems, Inc., Minneapolis, MN), goat polyclonal anti-VEGF-C antibody 1:100 (Santa Cruz Biotechnology, Inc.). After several washing steps using TBS, FITC-conjugated anti-hamster IgG antibody 1:1000, FITC-conjugated anti-rat IgG antibody 1:1000, FITC-conjugated anti-mouse IgG antibody 1:1000, Cy3-conjugated anti-rabbit IgG antibody 1:1000, Cy3-conjugated anti-rat IgG antibody 1:1000, Rhodamine-conjugated anti-goat IgG antibody 1:1000 were used as secondary antibodies. All secondary antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. Goat Fab fragment anti-mIgG (Jackson ImmunoResearch Laboratories, Inc.) was used to block endogenous mouse IgG to use mouse antibody on mouse tissue. Fluorescent signals were visualized and digital images were obtained using a Zeiss LSM 510 confocal microscope equipped with argon and helium-neon lasers (Carl Zeiss, Germany) or using a Zeiss ApoTome microscope coupled to a monochrome charge-coupled device camera (AxioVision, Carl Zeiss). Morphometric measurements of lymphatic and blood vessels in tumor and SLN were made from immunostained tissue sections by photographic analysis using ImageJ software (http://rsb.info.nih.gov/ij) after converting the images into 8-bit gray scale. Measurements of the number and size of the lymphatic vessels having lumen in tumor section were made at a screen magnification of 100×, each 0.84 mm2 in area. Measurements of the densities of the blood vessels in tumor section were made at a screen magnification of 100×, each 0.84 mm2 in area, whereas those and pan-cytokeratin stained cancer cells in SLN were made in total sectioned area (0.3-1.2 mm2), and 4 to 5 mice were used per group. To exclude background fluorescence, only pixels over a certain level (>50 intensity value) were taken. Measurements of the densities of the lymphatic vessels and blood vessels in the whole mount staining of bladder were made on whole fields at a screen magnification of 25×, relative densities were calculated in each 1.16 mm2 in area, and 4-5 mice were used per group. Values were expressed as relative densities (%). To measure the size of tumor and SLN, the mid-sectioned tissues were stained with H&E. The stained tissues were photographed with a Zeiss microscope, surface areas of mid-sectioned tumor and SLN were calculated using a Zeiss Apotome microscope coupled to monochrome charge-coupled device (CCD) camera and image analysis software (AxioVision, Zeiss).
Enrichment of CD11b+ cells from OUBC by FACS and RT-PCR
Primers for real-time RT-PCR
5'-CGT TCT CTG CCA GCA ACA TTA CCA C-3'
5'-CTT GTT GGG TCC ACA GAC ATC ATG G-3'
5'-GTC TGT AAA GCA CCA TGT CCG GGA G-3'
5'-CCA CAG GCT GGC TTT CTA CTT GCA C-3'
5'-CCT CAT GGA CTG ATT ATG GAC A-3'
5'-ATG TAA TCC AGC AGG TCA GCA A-3'
Administration of blocking or depletion agent
To block VEGF-C/D, the mice were treated with tail vein injections of 1.0 × 109 plaque-forming units (pfu) of adenovirus encoding soluble VEGFR-3 (Ade-sVR3) [25, 26] twice on the day and two weeks after the MBT-2 implantation. For systemic depletion of CD11b+/CD68+ TAM, the mice were treated with intraperitoneal injections of clodronate liposome (CDL, 25 mg/kg every 3 days i.p.) as previously described at 2 weeks after the tumor implantation . As a negative control, empty control liposome (CL) was injected in the same manner.
Values presented are means ± standard deviation (SD). Significant differences between means were determined by Student's t-test or analysis of variance followed by the Student-Newman-Keuls test. The accepted level of statistical significance was p < 0.05.
OUBC presents profound lymphangiogenesis, angiogenesis and TAM infiltration in tumor mass
OUBC displays marked lymphatic enlargement and increased number of blood vessels in the peritoneal surface of bladder wall
OUBC showed lymphatic metastasis of cancer cells to medial iliac lymph node
VEGFR-3 expressing CD11b+ TAM is the source of VEGF-C/D
Blockade of VEGF-C/D by soluble extracellular domain of VEGFR-3 suppressed OUBC-induced lymphangiogenesis and lymphatic metastasis to SLN but not CD11b+ TAM recruitment
CD11b+ TAM plays a crucial role in OUBC-induced lymphangiogenesis
Lymphatic metastasis of the OUBC was strongly inhibited by depletion of CD11b+ TAM
To elucidate the role of CD11b + TAM in lymphatic metastasis in the OUBC, the SLN of CDL and CL treated mice were examined. Treatment with CDL, but not CL, reduced the growth of lymphatic and blood vessels in the SLN (Figure 6F left). The densities of lymphatic and blood vessels in the SLN were decreased by about 30% and 40% in the CDL treatment compared to the CL treatment, respectively (Figure 6G). The lymphatic metastasis to the SLN was remarkably decreased by 70% in the CDL treated group when compared to the CL treated control group (Figure 6F right and 6H), indicating that CD11b+ TAM play crucial role in lymphatic metastasis of bladder cancer cells.
To establish distant metastasis, bladder tumor cells spread from the bladder to target organs through three main routes: hematogenous spread, lymphatic spread, and direct seeding. In bladder cancer, lymph node was known as the most common site of metastasis. Nearly 70% of bladder cancer patients experience lymphatic metastasis in the course of disease progression ; thus, lymph node metastasis is an important initial step toward distant metastasis .
In present study, OUBC model was an invasive bladder cancer which invades all layers of bladder wall and displayed profound lymphangiogenesis in primary tumor mass and SLN. Because TAM is known to play an important role in tumor lymphangiogenesis by secreting lymphangiogenic growth factor in other type of cancers [20–22], we proposed that profound lymphangiogenesis is associated with TAM, and bladder cancer cells can actively metastasize through lymphatic vessels with the help of TAM. In fact, one previous report indicates that TAM is frequently observed in clinical samples of bladder cancer , and that patients with high TAM count showed higher frequencies of vascular invasion and distant metastasis, and have lower 5-year survival rates than those with low TAM count. Moreover, the TAM count and microvessel densities were positively correlated to each other. Indeed, the present study showed that there are massive infiltration of CD11b+ macrophages located near the lymphatic vessels in primary tumor and SLN. Moreover, immunofluorescence staining for the markers such as CD68 and F4/80 revealed that most of TAM is the tumor and metastasis-promoting M2-type .
The depletion of TAM by using CDL dramatically decreased the lymphangiogenesis in tumor and SLN and suppressed lymphatic metastasis of tumor cells to SLN, indicating that TAM is an important pro-lymphangiogenic and pro-metastatic modulator in the bladder tumor. In addition to increasing the number of lymphatic vessels, TAM is able to condition the vessels to be vulnerable to intravasation of tumor cells: TAM facilitates migration and intravasation of tumor cells by secreting growth factors and chemotactic factors, and by remodeling the extracellular matrix through collagen fibril formation . Therefore, in the present study, it was possible that the anti-metastatic effect of CDL treatment might have resulted from not only the suppression of TAM-induced angiogenesis and lymphangiogenesis, but also from the inhibition of TAM-induced tumor cell migration and intravasation. However, contrary to previous report , depletion of TAM by CDL did not significantly reduce the tumor mass in the bladder. This could have resulted from the different characteristics of tumors in growing different organs. This orthotopic tumor grows mainly into the bladder cavity without invading its supporting tissues, a growth pattern that is quite different from that of other solid tumors.
Interestingly, CD11b+/CD68+ TAM expresses higher levels of VEGF-C/D than CD11b- cells, which were also known as the main mediator of tumor-associated lymphangiogenesis and lymphatic metastasis. Because CD11b+/CD68+ TAM flocked near the lymphatic vessels and VEGFR-3 was highly expressed in the lymphatic vascular endothelial cells, TAM could assist tumor-induced lymphangiogenesis by paracrine secretion of VEGF-C/D in bladder cancer. Moreover, co-immunostaining results showed that VEGFR-3 is also highly expressed in the CD11b+ TAM in itself, indicating that TAM may have autocrine and paracrine positive feedback loop to boost further secretion of VEGF-C/D. Consequently, once TAM is activated to become M2-type, it could accelerate lymphangiogenesis and lymphatic metastasis by the paracrine and autocrine mechanism. From this study, we could not exclude the partial contribution of tumor cells to the source of VEGF-C/D. Nevertheless, we were able to exclude the idea that tumor cells are the main source of tumor lymphangiogenesis, because depletion of macrophages by the CDL treatment caused >80% reduction in VEGF-C/D expressions in the tumor mass compared to the control CL treatment.
In addition, present data also indicate that the suppression of VEGF-C/D signaling by adenoviral delivery of sVR3 significantly reduced the growth of lymphatic vessels in bladder tumor and SLN and eventually inhibited lymphatic metastasis of bladder tumor cells from primary tumor to SLN without significant reductions of tumor mass and blood vessels in OUBC. These findings are mostly consistent with previously reported findings in the different tumor models [11–13]. Therefore, we postulated that lymphatic spread of cancer metastasis in patients with bladder cancer can be prevented by specific suppression of VEGF-C/D-VEGFR3 signaling pathways. But, this strategy seemed to have a limitation when reducing preformed tumor burden. In other words, because blocking lymphangiogenesis is rather tumoristatic than tumoricidal, blocking VEGF-C/D might be particularly useful when tumor burden is minimal, for example in the postoperative adjuvant setting. In comparison, recent studies [35, 36] show that VEGFR-3 is upregulated in the tumor vasculature; also, loss-of-function studies by genetic targeting of VEGFR-3 or blocking of its signaling with monoclonal antibodies resulted in decreased sprouting, indicating that VEGFR-3 has a role in angiogenic sprouting formation. The discrepancies in responsiveness to VEGFR-3 blocking experiments could have resulted from the different expression level of VEGFR-3 in the tumor vasculatures in varying tumor models. Indeed, the vasculatures and the sizes of our bladder cancer models are not responsive to the soluble VEGFR-3 treatment, which might be due to the low expression of VEGFR-3 in the tumor vasculatures.
Until now, even after successful radical cystectomy and lymph node dissection, about 50% of bladder cancer patients eventually show recurrence and have poor survival . For more than 30 years, there have been many efforts to reduce the recurrence of high-risk bladder cancer after curative surgery, however, numerous clinical trials failed to show conclusive evidence on the impact of adjuvant chemotherapy even by using the most toxic combination regimens . Considering these facts, blocking VEGF-C/D pathway and lymphangiogenesis could be another attractive alternative to reduce the recurrence of bladder tumor after curative radical cystectomy.
In summary, a profound OUBC-induced lymphangiogenesis in primary cancer and SLN contribute to lymphatic metastasis by VEGF-C/D and VEGFR-3 signaling. Infiltrated CD11b+/CD68+ TAM is intensely involved in OUBC-induced lymphangiogenesis and lymphatic metastasis and therefore TAM could be the bridge between primary cancer and SLN. Our study, which shows the therapeutic inhibition of lymphangiogenesis, provides another therapeutic target to inhibit lymphatic metastasis and recurrence in patients with invasive bladder cancer.
This work was supported by the grant (A092255, GYK) of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Korea. We thank Dr. Warren Heston for MBT-2 cell line and Yuna Hong, Eun Soon Lee, and Tae Chang Yang for their technical assistance.
- Hussain S, James N: The systemic treatment of advanced and metastatic bladder cancer. The Lancet Oncology. 2003, 4: 489-497. 10.1016/S1470-2045(03)01168-9View ArticlePubMedGoogle Scholar
- Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD: Metastatic Pattern of Bladder Cancer: Correlation With the Characteristics of the Primary Tumor. Am J Roentgen. 2011, 196: 117-10.2214/AJR.10.5036. 10.2214/AJR.10.5036View ArticleGoogle Scholar
- Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995, 87: 1603-1612. 10.1093/jnci/87.21.1603View ArticlePubMedGoogle Scholar
- Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000, 6: 4866-4873.PubMedGoogle Scholar
- Fernandez MI, Bolenz C, Trojan L, Steidler A, Weiss C, Alken P, Grobholz R, Michel MS: Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. Eur Urol. 2008, 53: 571-578. 10.1016/j.eururo.2007.08.030View ArticlePubMedGoogle Scholar
- Saban MR, Towner R, Smith N, Abbott A, Neeman M, Davis CA, Simpson C, Maier J, Memet S, Wu XR, Saban R: Lymphatic vessel density and function in experimental bladder cancer. BMC Cancer. 2007, 7: 219- 10.1186/1471-2407-7-219PubMed CentralView ArticlePubMedGoogle Scholar
- Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature. 2005, 438: 946-953. 10.1038/nature04480View ArticlePubMedGoogle Scholar
- Karpanen T, Alitalo K: Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol. 2008, 3: 367-397. 10.1146/annurev.pathmechdis.3.121806.151515View ArticlePubMedGoogle Scholar
- He Y, Karpanen T, Alitalo K: Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta. 2004, 1654: 3-12.PubMedGoogle Scholar
- Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M: VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood. 2007, 109: 1010-1017. 10.1182/blood-2006-05-021758PubMed CentralView ArticlePubMedGoogle Scholar
- Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002, 2: 573-583. 10.1038/nrc863View ArticlePubMedGoogle Scholar
- He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002, 94: 819-825.View ArticlePubMedGoogle Scholar
- Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP, Jain RK: Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 2006, 66: 8065-8075. 10.1158/0008-5472.CAN-06-1392View ArticlePubMedGoogle Scholar
- Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y: Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005, 65: 6901-6909. 10.1158/0008-5472.CAN-05-0408View ArticlePubMedGoogle Scholar
- Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006, 66: 2650-2657. 10.1158/0008-5472.CAN-05-1843View ArticlePubMedGoogle Scholar
- Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, Hayashi T, Kanetake H: Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res. 2006, 12: 800-806. 10.1158/1078-0432.CCR-05-1284View ArticlePubMedGoogle Scholar
- Suzuki K, Morita T, Tokue A: Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol. 2005, 12: 152-158. 10.1111/j.1442-2042.2005.01010.xView ArticlePubMedGoogle Scholar
- Murdoch C, Muthana M, Coffelt SB, Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008, 8: 618-631. 10.1038/nrc2444View ArticlePubMedGoogle Scholar
- Lamagna C, Aurrand-Lions M, Imhof BA: Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol. 2006, 80: 705-713. 10.1189/jlb.1105656View ArticlePubMedGoogle Scholar
- Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66: 605-612. 10.1158/0008-5472.CAN-05-4005View ArticlePubMedGoogle Scholar
- Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, Miyazono K: Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 2007, 67: 10181-10189. 10.1158/0008-5472.CAN-07-2366View ArticlePubMedGoogle Scholar
- Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS: Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 2008, 68: 1100-1109. 10.1158/0008-5472.CAN-07-2572View ArticlePubMedGoogle Scholar
- Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D: Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002, 161: 947-956. 10.1016/S0002-9440(10)64255-1PubMed CentralView ArticlePubMedGoogle Scholar
- Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD: Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 2000, 7: 844-851. 10.1038/sj.gt.3301157View ArticlePubMedGoogle Scholar
- Karpanen T, Egeblad M, Karkkainen M, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001, 61: 1786-PubMedGoogle Scholar
- He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K: Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65: 4739- 10.1158/0008-5472.CAN-04-4576View ArticlePubMedGoogle Scholar
- Jeffers MD, O'Dowd GM, Mulcahy H, Stagg M, O'Donoghue DP, Toner M: The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol. 1994, 172: 183-187. 10.1002/path.1711720205View ArticlePubMedGoogle Scholar
- Cheng L, Montironi R, Davidson D, Lopez-Beltran A: Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology. 2009, 22: S70-S95. 10.1038/modpathol.2009.1View ArticlePubMedGoogle Scholar
- Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S: Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001, 7: 199-205. 10.1038/84651View ArticlePubMedGoogle Scholar
- Cho CH, Koh YJ, Han J, Sung HK, Jong Lee H, Morisada T, Schwendener RA, Brekken RA, Kang G, Oike Y: Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circ Res. 2007, 100: e47-57. 10.1161/01.RES.0000259564.92792.93View ArticlePubMedGoogle Scholar
- Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA: Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006, 95: 272-281. 10.1038/sj.bjc.6603240PubMed CentralView ArticlePubMedGoogle Scholar
- Rinderknecht M, Detmar M: Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008, 216: 347-354. 10.1002/jcp.21494View ArticlePubMedGoogle Scholar
- Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y: Prognostic value of tumor associated macrophage count in human bladder cancer. International J Urol. 2000, 7: 263-269. 10.1046/j.1442-2042.2000.00190.x. 10.1046/j.1442-2042.2000.00190.xView ArticleGoogle Scholar
- Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141: 39-51. 10.1016/j.cell.2010.03.014View ArticlePubMedGoogle Scholar
- Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008, 454: 656-660. 10.1038/nature07083View ArticlePubMedGoogle Scholar
- Tvorogov D, Anisimov A, Zheng W, Leppanen VM, Tammela T, Laurinavicius S, Holnthoner W, Helotera H, Holopainen T, Jeltsch M: Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell. 2010, 18: 630-640. 10.1016/j.ccr.2010.11.001View ArticlePubMedGoogle Scholar
- Flechon A, Droz J: Chemotherapy practices and perspectives in invasive bladder cancer. Exp Rev Anticancer Thera. 2006, 6: 1473-1482. 10.1586/14737184.108.40.2063. 10.1586/14737220.127.116.113View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.